Skip to main navigation
menu

Aclaris - Corp Menu

  • About Us »
    « Back
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Compliance
    • Contact
  • Research »
    « Back
    • Diseases and Conditions
    • Pipeline
    • Drug Discovery
    • Clinical Trials
    • Publications
    • Investigator Initiated Studies
  • Partnerships
  • Products
  • Careers
  • Citizenship »
    « Back
    • Social Responsibility
    • Scientist Development Program
    • Aclaris Support
  • Insights
  • Investors »
    « Back
    • Investor Overview
    • Stock Information
    • Press Releases
    • Events
    • Investor Presentations
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
    • Email Alerts

Aclaris - Extras Menu

  • Media resources
  • Contact us

Aclaris - Corp Menu

  • About Us »
    « Back
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Compliance
    • Contact
  • Research »
    « Back
    • Diseases and Conditions
    • Pipeline
    • Drug Discovery
    • Clinical Trials
    • Publications
    • Investigator Initiated Studies
  • Partnerships
  • Products
  • Careers
  • Citizenship »
    « Back
    • Social Responsibility
    • Scientist Development Program
    • Aclaris Support
  • Insights
  • Investors »
    « Back
    • Investor Overview
    • Stock Information
    • Press Releases
    • Events
    • Investor Presentations
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
    • Email Alerts

Aclaris - Investor Relations

  • Investor Overview
  • Stock Information
  • Press Releases
  • Events
  • SEC Filings
  • Corporate Governance
  • Investor Presentations
  • Investor FAQs
  • Email Alerts
Investor Contact
For investor related questions, please email
investors@aclaristx.com

Investor Presentations

Investor Presentations

ATI-450-RA-201 Phase 2a Preliminary Topline Data Presentation
Aclaris Therapeutics Company Overview - December 2020
IIT-2020-ATI-450-COVID-19 Presentation
THWART-1 and THWART-2 Phase 3 Results Presentation
R&D Day Presentation September 27, 2019

Aclaris - Footer Menu

  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Fraudulent Activity Notice
© 2021 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.